Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Development and Validation of an AI-Driven Motor Skill Assessment System for Children (AIMAS)

10. November 2026 aktualisiert von: Chang Gung Memorial Hospital

Developing an AI-Driven Motor Skill Assessment System for School Children and Children With Developmental Delay

This study aims to develop and validate the AI-Integrated Motor Assessment System (AIMAS) for evaluating motor skills in children aged 6 to 12 years. The study will include typically developing children and children with developmental delay or motor-related developmental disorders.

Participants will complete standardized gross and fine motor tasks while their movements are video-recorded for AI-based analysis. Some participants will also complete a standardized clinical motor assessment for comparison.

The study will evaluate the reliability, validity, and accuracy of AIMAS, including its ability to identify children with motor difficulties. The long-term goal is to establish AIMAS as an accessible and efficient screening tool that can support earlier referral for further professional assessment.

Studienübersicht

Detaillierte Beschreibung

This three-year study will develop and validate the AI-Integrated Motor Assessment System (AIMAS), an AI-based platform that uses video-recorded motor tasks and pose-estimation analysis to assess children's motor performance.

In Year 1, the study will expand the motion dataset, train the AI model, and evaluate reliability and validity. In Year 2, the model will be tested in a new population using measures including ROC curves, AUC, sensitivity, and specificity, and a motor developmental delay risk score will be developed. In Year 3, AIMAS will be evaluated in clinical and educational settings for feasibility, accuracy, and agreement with professional motor assessments.

Approximately 470 children aged 6 to 12 years will be enrolled, including typically developing children and children with developmental delay or motor-related developmental disorders. Participants will complete a one-time assessment involving gross and fine motor tasks, with video recordings collected for AI analysis. A subset will also complete a standardized motor assessment, such as the Bruininks-Oseretsky Test of Motor Proficiency, for criterion-related validation.

The overall goal is to establish AIMAS as a reliable, valid, and scalable screening tool for early identification of motor difficulties in children.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

470

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Taoyuan City
      • Taoyuan, Taoyuan City, Taiwan, 333
        • Rekrutierung
        • Linkou Chang Gung Memorial Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Jahre bis 12 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The study population will include children aged 6 to 12 years recruited from collaborating hospital outpatient clinics and elementary schools. Participants will include typically developing children and children with developmental delay or motor-related developmental disorders, such as developmental coordination disorder, developmental delay, intellectual disability, mild cerebral palsy, autism spectrum disorder, or other clinician-confirmed developmental motor disorders.

Beschreibung

Inclusion Criteria:

Developmental Delay With Motor Disorder Group:

  • Children aged 6 to 12 years.
  • Able to understand and follow the motor instructions required for the study.
  • Clinical diagnosis of developmental delay with motor disorder, such as developmental coordination disorder, developmental delay, intellectual disability, mild cerebral palsy, autism spectrum disorder, or another clinician-confirmed developmental motor disorder.

Typically Developing Group:

  • Children aged 6 to 12 years.
  • Able to understand and follow the motor instructions required for the study.
  • Typical developmental milestones with no history of developmental delay or diagnosed developmental disorder.

Exclusion Criteria:

Developmental Delay With Motor Disorder Group:

  • Acute illness that makes participation unsuitable.
  • Degenerative or progressive neurological disease.
  • Unable to safely complete motor tasks because of conditions such as fracture, physical discomfort, or pain.

Typically Developing Group:

  • Prior diagnosis of developmental delay, motor impairment, or another condition affecting motor performance.
  • Neurological disorder, genetic syndrome, or major congenital or acquired condition that could influence motor ability.
  • Possession of a disability certificate or prior professional identification of significant developmental concerns.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Typically Developing Group

Children aged 6 to 12 years with typical development will complete standardized gross and fine motor assessments with video recording for AI-based analysis using the AI-Integrated Motor Assessment System (AIMAS).

The AI-Integrated Motor Assessment System (AIMAS) is a video-based motor assessment system that uses artificial intelligence and pose-estimation analysis to evaluate gross and fine motor performance in children. Participants complete standardized motor tasks while their movements are video-recorded for AI-based analysis. A subset of participants also completes a standardized clinical motor assessment for validation of AIMAS results.

Developmental Delay With Motor Disorder Group

Children aged 6 to 12 years with developmental delay or motor-related developmental disorders will complete standardized gross and fine motor assessments with video recording for AI-based analysis using AIMAS.

The AI-Integrated Motor Assessment System (AIMAS) is a video-based motor assessment system that uses artificial intelligence and pose-estimation analysis to evaluate gross and fine motor performance in children. Participants complete standardized motor tasks while their movements are video-recorded for AI-based analysis. A subset of participants also completes a standardized clinical motor assessment for validation of AIMAS results.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Diagnostic Accuracy of AIMAS for Identifying Motor Developmental Difficulties
Zeitfenster: Baseline (Day 1)

Diagnostic accuracy of the AI-Integrated Motor Assessment System (AIMAS) in distinguishing typically developing children from children with developmental delay or motor-related developmental disorders. Classification performance will be quantified using the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity.

Baseline (Day 1)
Reliability of AIMAS
Zeitfenster: Baseline (Day 1) and repeat assessment (Week 1)

Reliability of the AI-Integrated Motor Assessment System (AIMAS) will be quantified using intraclass correlation coefficients (ICC) for inter-rater and test-retest reliability. Inter-rater reliability will be determined by comparing AIMAS measurements obtained from independent raters, while test-retest reliability will be assessed using repeated motor assessments of the same participants. Consistency of AI-based joint and pose estimation will also be examined.

Baseline (Day 1) and repeat assessment (Week 1)
Criterion Validity of AIMAS
Zeitfenster: Baseline (Day 1)

Criterion-related validity of the AI-Integrated Motor Assessment System (AIMAS) will be examined by comparing AIMAS-derived motor performance scores with scores obtained from a standardized clinical motor assessment, such as the Bruininks-Oseretsky Test of Motor Proficiency (BOT), in a subset of participants. Associations between AIMAS scores and standardized assessment scores will be quantified using correlation coefficients.

Baseline (Day 1)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Group Differences in AIMAS-Derived Motor Task Performance
Zeitfenster: Baseline (Day 1)

Motor task performance will be compared between typically developing children and children with developmental delay or motor-related developmental disorders using quantitative measures derived from the AI-Integrated Motor Assessment System (AIMAS). Outcomes will include task completion time (seconds), task performance accuracy (percentage of correctly completed task components), and joint range of motion (degrees), as applicable to the standardized motor tasks. Between-group differences will be analyzed for each prespecified motor performance measure.

Baseline (Day 1)
AIMAS-Derived Motor Developmental Delay Risk Score
Zeitfenster: Baseline (Day 1)

A motor developmental delay risk score will be generated using AIMAS-derived movement features and classification model outputs. The score will represent the estimated probability of motor developmental difficulties, ranging from 0 to 1, with higher values indicating greater predicted risk.

Baseline (Day 1)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Chia-Ling Chen, Chang Gung Memorial Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. September 2026

Primärer Abschluss (Geschätzt)

1. September 2029

Studienabschluss (Geschätzt)

1. September 2029

Studienanmeldedaten

Zuerst eingereicht

3. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren